Amneal Pharmaceuticals Q4 Adjusted EPS $0.14 Beats $0.09 Estimate, Sales $616.98M Miss $634.23M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals (NYSE:AMRX) reported Q4 adjusted EPS of $0.14, surpassing the $0.09 estimate, but its sales of $616.98M fell short of the $634.23M estimate. This represents a 39.13% decrease in EPS from last year, while sales saw a 1.18% increase.
March 01, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amneal Pharmaceuticals reported a mixed Q4 with EPS beating estimates but sales missing expectations. EPS decreased by 39.13% YOY, while sales increased by 1.18%.
The mixed results with an EPS beat but a miss on sales forecasts could lead to neutral short-term stock price movement. The significant EPS decrease YOY might concern investors, but the slight increase in sales shows some positive momentum.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100